Baxter International Inc. BAX is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its first quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below: Earnings: The Zacks Consensus Estimate remained steady at 29 cents per share over the last 60 days. Baxter’s adjusted earnings of 36 cents per share beat this estimate by 24.1% and increased almost 6% from the year-ago quarter. Revenues: Baxter posted revenues of $2.38 billion, beating the Zacks Consensus Estimate for revenues of $2.35 billion. At constant currency (cc), revenues increased 4% on a year-over-year basis. Key Stats: At cc, Hospital products revenues increased 4%, while Renal products inched up 5% from the year-ago quarter. Major Factors: Baxter now expects sales to increase 3% for full-year 2016, while adjusted earnings are now forecasted in the range of $1.59 to $1.67 per share (up from earlier guided range of $1.46 to $1.54 per share). For the second quarter, Baxter expects sales to grow 4%, at cc, while adjusted earnings is forecasted to be in the range of 38 to 40 cents per share.Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session. Check back later for our full write up on this Baxter International report later! Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BAXTER INTL (BAX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research